Skip to content

INDP

Indaptus Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.22
+5.17%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
R&D Expense5.2M9.3M7.3M7.6M6.3M
SG&A Expense9.6M10.5M8.1M8.8M8.6M
General & Admin Expense9.6M10.5M8.1M8.8M8.6M
Selling & Marketing Expense
Other Expenses0.00
Total Operating Expenses14.8M19.8M15.4M16.4M14.9M
Cost and Expenses14.8M19.8M15.4M16.4M14.9M
Operating Income (EBIT)(14.8M)(19.8M)(15.4M)(16.4M)(14.9M)
Non-Operating
Interest Income588.1K
Interest Expense
Net Interest Income588.1K
Other Non-Op Income/Expense(650.9K)(1.0M)343.7K955.0K588.1K
Non-Operating Income (excl Interest)678.9K1.0M(343.7K)(955.0K)(588.1K)
EBT (Pre-Tax Income)(15.4M)(20.8M)(15.0M)(15.4M)(14.3M)
Income Tax Expense
Bottom Line
Net Income(15.4M)(20.8M)(15.0M)(15.4M)(14.3M)
Earnings from Cont. Ops(15.4M)(20.8M)(15.0M)(15.4M)(14.3M)
Earnings from Discont. Ops
Bottom Line Net Income(15.4M)(20.8M)(15.0M)(15.4M)(14.3M)
Per Share
Basic EPS($6.97)($21.58)($44.96)($51.41)($48.54)
Diluted EPS($6.97)($21.58)($44.96)($51.41)($48.54)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding116.1M966124334132300037295075
Diluted Shares Outstanding116.1M966124334132300037295075
Profitability Metrics
EBITDA(15.5M)(20.8M)(15.0M)(15.4M)(14.3M)
D&A735.001.3K1.8K
EBIT(15.5M)(20.8M)(15.0M)(15.4M)(14.3M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026